Kura Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kura Oncology, Inc.
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
The cancer drug developer raised $55m. Also, Lyra raised $56m in the last of four biopharma IPOs in April, Biogen sold $3bn worth of debt, Oberland raised a $1.05bn fund and Praxis launched with more than $100m.
Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.
Public Company Edition: Long-struggling Regulus is laying off employees and pausing its two clinical programs. Also, Ironwood is shuffling staff ahead of splitting into two companies and will cut 40 jobs in the process. And among several loan agreements and note sales, Tesaro borrows another $200m.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Zeta Acquisition Corp III